ArticleExperimental and therapeutic medicine2013
Analysis of the expression levels of survivin and VEGF in patients with acute lymphoblastic leukemia.
Article in Experimental and therapeutic medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Article
- Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia.Oncotarget · 2018Article
- Implication of Gastric Cancer Molecular Genetic Markers in Surgical Practice.Current genomics · 2017Review
- Effects of bone marrow-derived mesenchymal stem cells transfected with survivin on pulmonary fibrosis in mice.Experimental and therapeutic medicine · 2015Article
- Lipopolysaccharide Effect on Vascular Endothelial Factor and Matrix Metalloproteinases in Leukemic Cell Lines In vitro.Iranian journal of cancer prevention · 2015Article
- Circulating survivin levels in healthy and asthmatic pregnancy.Reproductive biology and endocrinology : RB&E · 2014Article
- Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders.Journal of autism and developmental disorders · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to investigate the association between an inhibitor of apoptosis (survivin) and vascular endothelial growth factor (VEGF) expression in patients with acute lymphoblastic leukemia (ALL) prior to and following chemotherapy. Reverse transcription (RT)-PCR and western blotting were employed to analyze survivin and VEGF mRNA and protein expression. Moreover, the concentrations of survivin and VEGF were determined by enzyme-linked immunosorbent assay (ELISA). Our data revealed that survivin and VEGF were overexpressed in patients with ALL prior to treatment, while survivin levels were significantly decreased following treatment. In addition, there was a positive correlation between survivin and VEGF concentrations in plasma. In conclusion, analysis of survivin and VEGF expression levels may improve the clinical diagnosis and treatment of ALL.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.